Unknown

Dataset Information

0

The TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) Observational Study.


ABSTRACT: BACKGROUND:Bladder dysfunction is a common symptom of multiple sclerosis (MS). This study was designed to evaluate effects of natalizumab on bladder function in patients with relapsing-remitting MS. METHODS:The TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) study was an open-label, single-arm, two-center study. Natalizumab-naive MS patients with disabling bladder dysfunction and initiating natalizumab were enrolled and followed for 6 months. The primary endpoint was change in the Urogenital Distress Inventory short form (UDI-6) score from baseline. Change in Incontinence Impact Questionnaire short form (IIQ-7) score from baseline was a secondary endpoint. RESULTS:Thirty patients were enrolled. Mean baseline characteristics were age 49.9 years, Expanded Disability Status Scale score 4.6, number of relapses in previous year 2.4, UDI-6 score 10.4, and IIQ-7 score 12.3. Mean changes in UDI-6 and IIQ-7 scores were significantly improved from baseline beginning at week 4 and up to week 24; mean improvements at 24 weeks were 4.4 (P < .0001) and 4.9 (P = .0005) points, respectively. At week 24, 85.7% and 78.6% of patients demonstrated improvements from baseline in UDI-6 and IIQ-7 scores, respectively. CONCLUSIONS:Incontinence-related quality of life as measured by UDI-6 and IIQ-7 scores improved significantly during natalizumab treatment.

SUBMITTER: Khatri BO 

PROVIDER: S-EPMC3967702 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

The TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) Observational Study.

Khatri Bhupendra O BO   Foley John F JF   Fink Jennifer J   Kramer John F JF   Cha Choon C   You Xiaojun X   Warth John D JD   Foulds Pam P  

International journal of MS care 20140101 1


<h4>Background</h4>Bladder dysfunction is a common symptom of multiple sclerosis (MS). This study was designed to evaluate effects of natalizumab on bladder function in patients with relapsing-remitting MS.<h4>Methods</h4>The TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) study was an open-label, single-arm, two-center study. Natalizumab-naive MS patients with disabling bladder dysfunction and initiating natalizumab were enrolle  ...[more]

Similar Datasets

| S-EPMC10503252 | biostudies-literature
| S-EPMC8013024 | biostudies-literature
| S-EPMC8597184 | biostudies-literature
| S-EPMC8175839 | biostudies-literature
| S-EPMC8279996 | biostudies-literature
| S-EPMC3537666 | biostudies-literature
| S-EPMC5564279 | biostudies-other
| S-EPMC5794695 | biostudies-other
| S-EPMC8804113 | biostudies-literature
| S-EPMC10401910 | biostudies-literature